Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Short bowel syndrome (SBS) is an acquired condition characterized by insufficient intestinal absorptive capacity following surgical resection of a significant portion of the small intestine. The condition has no Mendelian inheritance patterns or causative gene variants documented in this packet.
Phenotypic data are not established in this packet.
SBS is an acquired post-surgical condition. No causative genes or inheritance patterns are documented in this packet.
Diagnostic criteria are not established in this packet.
Two categories of FDA-approved therapies with active market status are documented in this packet for SBS. The first is teduglutide (GATTEX), approved by NDA in December 2012. The second is multiple somatropin brands (GENOTROPIN, HUMATROPE, NORDITROPIN, NUTROPIN AQ, OMNITROPE, SAIZEN, SEROSTIM, ZOMACTON), all with active market status per the packet.
32 trials found
Prognostic information is not established in this packet.
One recruiting trial is documented in this packet: NCT06907862, a Phase 3 study of glepaglutide, sponsored by Zealand Pharma, with enrollment September 2025 to September 2028.
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:30 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning short bowel syndrome
Updated Jun 1, 2026
Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome.
A position paper from the Society for Paediatric Gastroenterology and Nutrition discusses the use of teduglutide in treating short bowel syndrome in infants, children, and adolescents. This guidance aims to inform clinical practices regarding chronic intestinal failure management.